ASCLETIS ANNOUNCES U.S. FDA IND CLEARANCE FOR 13-WEEK PHASE II STUDY OF ITS ORAL SMALL MOLECULE GLP-1, ASC30, IN PARTICIPANTS WITH DIABETES

Reuters · 6d ago

Please log in to view news